Aurobindo clarifies on proposal to halt Phase 3 trial in moderate Covid patients

Earlier during the year, Aurobindo Pharma Ltd entered into a non-exclusive voluntary licensing agreement with MSD Pharmaceuticals for their investigational antiviral drug (Covid-19) molnupiravir. The Company has completed the trials for molnupiravir in mild Covid-19 patients as per protocol and the results have come out exceedingly well. The data for the same has been submitted to the Drug Controller General of India (DCGI) already.

The Company has also conducted the trials for molnupiravir in 100 moderate Covid-19 patients. We have faced challenges in patient recruitment at this juncture and are evaluating further course of action.

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 720.40 as compared to the previous close of Rs. 715.00. The total number of shares traded during the day was 375159 in over 4192 trades.

The stock hit an intraday high of Rs. 724.90 and intraday low of 711.10. The net turnover during the day was Rs. 268658600.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 AUROPHARMA Pharmaceuticals Phase3Trial Halt Molnupiravir